ArticleBritish journal of haematology2024
Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.
Article in British journal of haematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 27 citations in OpenAlex.
- Rethinking Common Diagnoses: Idiopathic Multicentric Castleman Disease Presenting as TAFRO Syndrome: A Case Report.Clinical case reports · 2026Article
- Sustained Remission of More Than Five Years After Thalidomide-Cyclophosphamide-Prednisone Discontinuation in Idiopathic Multicentric Castleman Disease: A Single-Center Retrospective StudyTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026Article
- Real-World Usage and Outcomes of Different Siltuximab Dosing Frequency in Idiopathic Multicentric Castleman Disease.American journal of hematology · 2026Article
- Deciphering the full spectrum of Castleman diseases based on a cohort of 700 patients in a western country.British journal of haematology · 2026Article
- Serum interleukin-6 (Il-6) monitoring in idiopathic multicentric Castleman disease: important value in patients receiving non-anti-Il-6 therapy.Biomarker research · 2026Article
- Distinct interleukin-6 production in IPL and TAFRO subtypes of idiopathic multicentric Castleman disease.Haematologica · 2026Article
- Comprehensive analysis of subtype-specific outcomes and management in Castleman disease: a 20-year cohort study.Blood advances · 2026Article
- Limited discriminatory performance of the iMCD-IPI in a Western cohort.The oncologist · 2026Article
- Is "severe" idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy (IPL) really severe?HemaSphere · 2026Article
- Clusterin expression and germinal center morphometry help distinguish idiopathic multicentric castleman disease from select lymphadenopathies.Frontiers in immunology · 2026Article
- Expert Perspective: Diagnosis and Treatment of Castleman Disease.Arthritis & rheumatology (Hoboken, N.J.) · 2026Review
- Castleman disease: clinical features, pathology, and treatment outcomes in 12 cases.Frontiers in oncology · 2026Article
- The Clinicopathologic Spectrum of Rosai-Dorfman-Destombes Disease in Adults: An Analysis of 16 Cases.European journal of haematology · 2025Article
- Plasma Cell-rich Nephritis with a Systemic Polyclonal Lymphoproliferative Disorder, Mimicking Idiopathic Multicentric Castleman Disease, Systemic Lupus Erythematosus, and IgG4-related Disease.Internal medicine (Tokyo, Japan) · 2025Article
- Serum Soluble Interleukin-2 Receptor as a Potential Marker for Assessing Disease Activity in the TAFRO Subtype of Idiopathic Multicentric Castleman Disease.Internal medicine (Tokyo, Japan) · 2025Article
- The Involvement of PI3K-Akt Signaling in the Clinical and Pathological Findings of Idiopathic Multicentric Castleman Disease-Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, and Organomegaly and Not Otherwise Specified Subtypes.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025Article
- Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry.Blood advances · 2025Article
- LRG1, a novel serum biomarker for iMCD disease activity.Biomarker research · 2025Article
- Exploring the Clinical Diversity of Castleman Disease and TAFRO Syndrome: A Japanese Multicenter Study on Lymph Node Distribution Patterns.American journal of hematology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
Idiopathic multicentric Castleman disease (iMCD) is subclassified into iMCD-thrombocytopenia, anasarca, reticulin fibrosis, renal dysfunction, organomegaly (TAFRO) and iMCD-not otherwise specified (NOS) according to the Castleman Disease Collaborative Network (CDCN) consensus criteria. With a deeper understanding of iMCD, a group of patients with iMCD-NOS characterised by polyclonal hypergammaglobulinaemia, plasmacytic/mixed-type lymph node histopathology and thrombocytosis has attracted attention. This group of patients has been previously described as having idiopathic plasmacytic lymphadenopathy (IPL). Whether these patients should be excluded from the current classification system lacks sufficient evidence. This retrospective analysis of 228 patients with iMCD-NOS identified 103 (45.2%) patients with iMCD-IPL. The clinical features and outcomes of patients with iMCD-IPL and iMCD-NOS without IPL were compared. Patients with iMCD-IPL showed a significantly higher inflammatory state but longer overall survival. No significant difference in overall survival was observed between severe and non-severe patients in the iMCD-IPL group according to the CDCN severity classification. Compared with lymphoma-like treatments, multiple myeloma-like and IL-6-blocking treatment approaches in the iMCD-IPL group resulted in significantly higher response rates and longer time to the next treatment. These findings highlight the particularities of iMCD-IPL and suggest that it should be considered a new subtype of iMCD-NOS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.